Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.

Janine KirchbergLuise FischerPatrick BornFranziska BrunnerCharlotte MorgnerDaniel FürstSimone HeynEnrica BachMandy BruecknerMadlen JentzschSong-Yau WangSebastian BöttcherGeorg-Nikolaus FrankeHubert SchrezenmeierUwe PlatzbeckerMaximilian MerzVladan Vučinić

Published in: Clinical lymphoma, myeloma & leukemia (2024)

Our data confirm that the treatment with ide-cel is feasible for patients with prior allo-HSCT. Furthermore, allo-HSCT did not influence cellular composition of lymphocyte collections, clinical outcome or in vivo expansion of ide-cel.

Keyphrases

allogeneic hematopoietic stem cell transplantation
multiple myeloma
acute myeloid leukemia
acute lymphoblastic leukemia
stem cells
machine learning
electronic health record
combination therapy
cell therapy
hematopoietic stem cell
artificial intelligence